nach oben

Lung

Erschienen in:

01.10.2018 | AIRWAYS DISEASE

Increased Sputum IL-17A Level in Non-asthmatic Eosinophilic Bronchitis

verfasst von: Chen Zhan, Rong Xu, Jiaxing Liu, Shengfang Zhang, Wei Luo, Ruchong Chen, Kefang Lai

Erschienen in: Lung | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Non-asthmatic eosinophilic bronchitis (NAEB) is one common cause of chronic cough which is characterized as airway eosinophilic inflammation like asthma but lack of airway hyper-responsiveness. Previous studies showed that Th2-pathway plays a role in NAEB, but the role of non-Th2 pathway in mechanism of NAEB remains unknown. Recently, IL-17A, a Th17-pathway cytokine, has been demonstrated to be involved in asthma development. However, the relationship between Th17-pathway and NAEB is unknown.

Methods

We aim to assess the airway level of IL-17A in the subjects with NAEB. Relationships between the IL-17A level and airway function in NAEB or asthma are also observed. We measured IL-17A concentrations in the sputum supernatant from 12 subjects with EB, 16 subjects with asthma [9 eosinophilic asthmatic (EA) and 7 non-eosinophilic asthmatic (NEA) according to the sputum eosinophil ≥ 3%], and 9 healthy control subjects.

Results

Increasing IL-17A level was found in NAEB group (29.65 ± 8.13 pg/ml), EA group (32.45 ± 3.22 pg/ml), and NEA group (29.62 ± 6.91 pg/ml) compared with the healthy control group (17.05 ± 10.30 pg/ml) (P < 0.05, P < 0.01, P < 0.05, respectively). The sputum IL-17A level was correlated with FENO (r = 0.44, P < 0.01), FEV1/FVC% (r = − 0.38, P < 0.05), MMEF%pred (r = − 0.34, P < 0.05), and sputum neutrophil% (r = 0.33, P < 0.05) in total.

Conclusion

Th17-pathway may play a role not only in asthmatics, but also in subjects with NAEB, as reflected by increasing IL-17A concentrations in sputum supernatant.

Gibson PG, Dolovich J, Denburg J et al (1989) Chronic cough: eosinophilic bronchitis without asthma. Lancet 1:1346–1348. https://doi.org/10.1016/S0140-6736(89)92801-8 CrossRefPubMed

Brightling CE, Ward R, Goh KL et al (1999) Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 160:406–410. https://doi.org/10.1164/ajrccm.160.2.9810100 CrossRefPubMed

Joo JH, Park SJ, Park SW et al (2002) Clinical features of eosinophilic bronchitis. Korean J Intern Med 17:31–37. https://doi.org/10.3904/kjim.2002.17.1.31 CrossRefPubMedPubMedCentral

Pratter MR (2006) Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. Chest 129:59S–62S. https://doi.org/10.1378/chest.129.1_suppl.59S CrossRefPubMed

Lai K, Pan J, Chen R et al (2013) Epidemiology of cough in relation to China. Cough. https://doi.org/10.1186/1745-9974-9-18 CrossRefPubMedPubMedCentral

Lai K, Chen R, Lin J et al (2013) A prospective, multicenter survey on causes of chronic cough in China. Chest 143:613–620. https://doi.org/10.1378/chest.12-0441 CrossRefPubMed

Berry MA, Parker D, Neale N et al (2004) Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 114:1106–1109. https://doi.org/10.1016/j.jaci.2004.08.032 CrossRefPubMed

Brightling CE, Bradding P, Symon FA et al (2002) Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346:1699–1705. https://doi.org/10.1056/NEJMoa012705 CrossRefPubMed

Lai K, Liu B, Xu D et al (2015) Will nonasthmatic eosinophilic bronchitis develop into chronic airway obstruction? A prospective, observational study. Chest 148:887–894. https://doi.org/10.1378/chest.14-2351 CrossRefPubMed

10.

Brightling CE, Symon FA, Birring SS et al (2002) TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol 110:899–905CrossRefPubMed

11.

Brightling CE, Symon FA, Birring SS et al (2003) Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax 58:528–532. https://doi.org/10.1136/thorax.58.6.528 CrossRefPubMedPubMedCentral

12.

Brightling CE, Ward R, Woltmann G et al (2000) Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med 162:878–882. https://doi.org/10.1164/ajrccm.162.3.9909064 CrossRefPubMed

13.

Birring SS, Parker D, Brightling CE et al (2004) Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med 169:15–19. https://doi.org/10.1164/rccm.200308-1092OC CrossRefPubMed

14.

Zhang R, Luo W, Liang Z et al (2017) Eotaxin and IL-4 levels are increased in induced sputum and correlate with sputum eosinophils in patients with nonasthmatic eosinophilic bronchitis. Medicine. https://doi.org/10.1097/MD.0000000000006492 CrossRefPubMedPubMedCentral

15.

Bao W, Liu P, Qiu Z et al (2015) Efficacy of add-on montelukast in nonasthmatic eosinophilic bronchitis: the additive effect on airway inflammation, cough and life quality. Chin Med J 128:39–45. https://doi.org/10.4103/0366-6999.147805 CrossRefPubMedPubMedCentral

16.

Cai C, He M-Z, Zhong S-Q et al (2012) Add-on montelukast vs double-dose budesonide in nonasthmatic eosinophilic bronchitis: a pilot study. Respir Med 106:1369–1375. https://doi.org/10.1016/j.rmed.2012.06.009 CrossRefPubMed

17.

Moore WC, Meyers DA, Wenzel SE et al (2010) Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181:315–323. https://doi.org/10.1164/rccm.200906-0896OC CrossRefPubMed

18.

Wenzel SE (2012) Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18:716–725. https://doi.org/10.1038/nm.2678 CrossRefPubMed

19.

Ishigame H, Kakuta S, Nagai T et al (2009) Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30:108–119. https://doi.org/10.1016/j.immuni.2008.11.009 CrossRefPubMed

20.

Jovanovic DV, Di Battista JA, Martel-Pelletier J et al (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:3513–3521PubMed

21.

Isailovic N, Daigo K, Mantovani A, Selmi C (2015) Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun 60:1–11. https://doi.org/10.1016/j.jaut.2015.04.006 CrossRefPubMed

22.

Chien J-W, Lin C-Y, Yang KD et al (2013) Increased IL-17A secreting CD4⁺ T cells, serum IL-17 levels and exhaled nitric oxide are correlated with childhood asthma severity. Clin Exp Allergy 43:1018–1026. https://doi.org/10.1111/cea.12119 CrossRefPubMed

23.

Hasegawa T, Uga H, Mori A, Kurata H (2017) Increased serum IL-17A and Th2 cytokine levels in patients with severe uncontrolled asthma. Eur Cytokine Netw 28:8–18. https://doi.org/10.1684/ecn.2017.0390 CrossRefPubMed

24.

Sorbello V, Ciprandi G, Di Stefano A et al (2015) Nasal IL-17F is related to bronchial IL-17F/neutrophilia and exacerbations in stable atopic severe asthma. Allergy 70:236–240. https://doi.org/10.1111/all.12547 CrossRefPubMed

25.

Zijlstra GJ, Hacken Ten NHT, Hoffmann RF et al (2012) Interleukin-17A induces glucocorticoid insensitivity in human bronchial epithelial cells. Eur Respir J 39:439–445. https://doi.org/10.1183/09031936.00017911 CrossRefPubMed

26.

Brightling CE (2006) Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 129:116S–121S. https://doi.org/10.1378/chest.129.1_suppl.116S CrossRefPubMed

27.

Lai K (2014) Chinese national guidelines on diagnosis and management of cough: consensus and controversy. J Thorac Dis 6:S683–S688. https://doi.org/10.3978/j.issn.2072-1439.2014.10.06 CrossRefPubMedPubMedCentral

28.

Global Initiative for Asthma (2017) Global strategy for asthma management and prevention. Available at https://ginasthma.org/gina-reports/

29.

American Thoracic Society, European Respiratory Society (2005) ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 171:912–930. https://doi.org/10.1164/rccm.200406-710ST CrossRef

30.

Miller MR, Hankinson J, Brusasco V et al (2005) Standardisation of spirometry. Eur Respir J 26:319–338. https://doi.org/10.1183/09031936.05.00034805 CrossRefPubMed

31.

Pizzichini E, Pizzichini MM, Efthimiadis A et al (1996) Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 154:308–317. https://doi.org/10.1164/ajrccm.154.2.8756799 CrossRefPubMed

32.

Paggiaro PL, Chanez P, Holz O et al (2002) Sputum induction. Eur Respir J Suppl 37:3s–8sPubMed

33.

Fireman E (2003) Induced sputum as a diagnostic tactic in pulmonary diseases. Isr Med Assoc J 5:524–527PubMed

34.

Luo W, Chen Q, Chen R et al (2017) Reference value of induced sputum cell counts and its relationship with age in healthy adults in Guangzhou, Southern China. Clin Respir J. https://doi.org/10.1111/crj.12645 CrossRefPubMed

35.

Pavord ID, Shaw DE, Gibson PG, Taylor DR (2008) Inflammometry to assess airway diseases. Lancet 372:1017–1019. https://doi.org/10.1016/S0140-6736(08)61421-X CrossRefPubMed

36.

Gibson PG (2009) Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J 3:198–206. https://doi.org/10.1111/j.1752-699X.2009.00162.x CrossRefPubMed

37.

Molet S, Hamid Q, Davoine F et al (2001) IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 108:430–438. https://doi.org/10.1067/mai.2001.117929 CrossRefPubMed

38.

Seys SF, Grabowski M, Adriaensen W et al (2013) Sputum cytokine mapping reveals an “IL-5, IL-17A, IL-25-high” pattern associated with poorly controlled asthma. Clin Exp Allergy 43:1009–1017. https://doi.org/10.1111/cea.12125 CrossRefPubMed

39.

Chambers ES, Nanzer AM, Pfeffer PE et al (2015) Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: potential benefits of calcitriol. J Allergy Clin Immunol 136:628–637. https://doi.org/10.1016/j.jaci.2015.01.026 CrossRefPubMedPubMedCentral

40.

Rahman MS, Yamasaki A, Yang J et al (2006) IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK, and p38) pathways. J Immunol 177:4064–4071CrossRefPubMed

41.

Wakashin H, Hirose K, Maezawa Y et al (2008) IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med 178:1023–1032. https://doi.org/10.1164/rccm.200801-086OC CrossRefPubMed

42.

Bullens DMA, Truyen E, Coteur L et al (2006) IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res. https://doi.org/10.1186/1465-9921-7-135 CrossRefPubMedPubMedCentral

43.

Lane C, Knight D, Burgess S et al (2004) Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. Thorax 59:757–760. https://doi.org/10.1136/thx.2003.014894 CrossRefPubMedPubMedCentral

44.

Ouyang W, Kolls JK, Zheng Y (2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28:454–467. https://doi.org/10.1016/j.immuni.2008.03.004 CrossRefPubMedPubMedCentral

45.

Miljkovic D, Cvetkovic I, Vuckovic O et al (2003) The role of interleukin-17 in inducible nitric oxide synthase-mediated nitric oxide production in endothelial cells. Cell Mol Life Sci 60:518–525CrossRefPubMed

46.

Cai L, Suboc P, Hogue DA et al (2002) Interleukin 17 induced nitric oxide suppresses matrix synthesis and protects cartilage from matrix breakdown. J Rheumatol 29:1725–1736PubMed

Titel: Increased Sputum IL-17A Level in Non-asthmatic Eosinophilic Bronchitis
verfasst von: Chen Zhan
Rong Xu
Jiaxing Liu
Shengfang Zhang
Wei Luo
Ruchong Chen
Kefang Lai
Publikationsdatum: 01.10.2018
Verlag: Springer US
Erschienen in: Lung / Ausgabe 6/2018
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-018-0166-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Increased Sputum IL-17A Level in Non-asthmatic Eosinophilic Bronchitis

Abstract

Background

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Endothelial Function in COPD Is in an Intermediate Position Between Healthy Subjects and Coronary Artery Disease Patients and Is Related to Physical Activity

Prognostic Factors in Adult Patients with Non-Cystic Fibrosis Bronchiectasis

The Diagnostic Yield, Safety, and Impact of Flexible Bronchoscopy in Non-HIV Immunocompromised Critically Ill Patients in the Intensive Care Unit

Association of Radiological Findings with the Xpert MTB/RIF Test in Patients with Suspected Pulmonary Tuberculosis

Annexin A5 Protein as a Potential Biomarker for the Diagnosis of Asthma

TIMP-1 Promotes the Immune Response in Influenza-Induced Acute Lung Injury

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin